TransMedics Group (NASDAQ:TMDX) CFO Gerardo Hernandez Sells 375 Shares

TransMedics Group, Inc. (NASDAQ:TMDX) CFO Gerardo Hernandez sold 375 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $52,170.00. Following the completion of the transaction, the chief financial officer owned 14,689 shares in the company, valued at approximately $2,043,533.68. This trade represents a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Gerardo Hernandez also recently made the following trade(s):

• On Wednesday, March 4th, Gerardo Hernandez sold 7,236 shares of TransMedics Group stock. The stock was sold at an average price of $147.21, for a total value of $1,065,211.56.
• On Thursday, December 4th, Gerardo Hernandez sold 920 shares of TransMedics Group stock. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40.

TransMedics Group Trading Down 6.2%

TMDX stock traded down $9.22 during midday trading on Thursday, reaching $138.44. 290,500 shares of the company’s stock traded hands, compared to its average volume of 802,945. The company has a debt-to-equity ratio of 1.06, a current ratio of 7.14 and a quick ratio of 6.59. TransMedics Group, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $156.00. The business has a 50-day moving average price of $134.97 and a two-hundred day moving average price of $126.78. The company has a market capitalization of $4.75 billion, a P/E ratio of 28.25 and a beta of 1.98.

Analysts Set New Price Targets

TMDX has been the topic of several research reports. Wall Street Zen lowered TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Oppenheimer boosted their price target on TransMedics Group from $150.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Piper Sandler lifted their price objective on shares of TransMedics Group from $140.00 to $160.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. JPMorgan Chase & Co. boosted their target price on shares of TransMedics Group from $114.00 to $149.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Finally, Morgan Stanley raised their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday, December 2nd. Six research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, TransMedics Group has an average rating of “Moderate Buy” and a consensus price target of $150.67.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently bought and sold shares of TMDX. Vanguard Group Inc. increased its holdings in TransMedics Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock valued at $404,549,000 after buying an additional 9,650 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after acquiring an additional 113,817 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of TransMedics Group by 50.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company’s stock valued at $117,506,000 after acquiring an additional 322,353 shares during the last quarter. Geode Capital Management LLC raised its position in shares of TransMedics Group by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 816,474 shares of the company’s stock valued at $99,339,000 after acquiring an additional 2,903 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after purchasing an additional 223,409 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.